News
The Europe glucagon-like peptide-1 (GLP-1) agonists market is projected to witness significant growth, fueled primarily by an increased prevalence of type 2 diabetes and obesity.
The intricate interplay between pancreatic beta cells and glucagon-like peptide-1 (GLP-1) has drawn considerable attention in efforts to improve the diagnosis and treatment of diabetes and ...
Oxyntomodulin (OXM) is a peptide hormone released by intestinal L cells after food intake. It acts as a dual agonist of glucagon-like peptide 1 (GLP-1) and glucagon receptors, regulating appetite, ...
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is), originally developed for type 2 diabetes treatment, have demonstrated in randomised ...
License agreement supports Madrigal’s pipeline strategy to develop innovative combination treatments for MASH, anchored by its foundational therapy Rezdiffra™ (resmetirom) Combining Rezdiffra with the ...
LipoVive Releases Ingredient Report Comparing Natural GLP-1 Support to Synthetic Drugs Like Mounjaro
A Plant-Based Formula With Science-Referenced Compounds Designed to Support Hormonal Weight Balance Without Prescription ...
2d
News-Medical.Net on MSNWhich GLP-1 meds have the most side effects? Study of 60,000 Facebook posts gives answers
Researchers analyzed nearly 60,000 public Facebook posts to identify real-world adverse events linked to GLP-1 receptor ...
For older patients with cancer and type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is ...
For older adults with diabetes, there is no clear evidence to suggest that the incidence of dementia differs for those using ...
6d
HealthDay on MSNGLP-1 Receptor Agonists Tied to Decrease in T2DM-Related Dementia Risk
Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with reduced type 2 diabetes mellitus (T2DM)-related ...
7d
News-Medical.Net on MSNCan one drug do it all? Reviewing the expanding clinical universe of GLP-1 agonists
Landmark trials have shown that GLP-1 receptor agonists, originally developed for diabetes and weight loss, also provide ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results